Evidence map›Paper›PMID 38312174›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2024

Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients.

Mona ElTagui, Mona El-Ghamrawy, Shareef Karam AlDeeb, Mariam Saad Nassim

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06606886 (Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06606886 phase4completednot on this map

Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia

TypeinterventionalSponsorBahria UniversityRan2024 to 2026Enrolled96ConditionsTransfusion Dependent Beta-thalassemiaArmsTablet Metformin (Group A), Tablet Hydroxyurea (Group B)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mona ElTaguiDepartment of Paediatrics, Kasr Alainy Faculty of Medicine, Cairo University, 42 Ali Ibrahim Ramez Street, Behind Heliopolis Hospital, El Nohza, Cairo, Egypt.
Mona El-GhamrawyDepartment of Paediatrics, Kasr Alainy Faculty of Medicine, Cairo University, 42 Ali Ibrahim Ramez Street, Behind Heliopolis Hospital, El Nohza, Cairo, Egypt.
Shareef Karam AlDeebDepartment of Paediatrics, Kasr Alainy Faculty of Medicine, Cairo University, 42 Ali Ibrahim Ramez Street, Behind Heliopolis Hospital, El Nohza, Cairo, Egypt.
Mariam Saad NassimDepartment of Paediatrics, Kasr Alainy Faculty of Medicine, Cairo University, 42 Ali Ibrahim Ramez Street, Behind Heliopolis Hospital, El Nohza, Cairo, Egypt.
Cairo University · EGHeliopolis University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-transfusion dependent thalassemia (NTDT) refers to a group of thalassemic disorders who do not need regular transfusions for survival, however it may be needed in certain conditions. Metformin was reported as a potential fetal hemoglobin (HbF) inducing agent in vitro but its efficacy and safety in vivo was not fully studied. This is a prospective interventional study aimed at studying the effect of metformin on HbF change in NTDT.

methodsPatients with established diagnosis of NTDT were enrolled. They were receiving a stable fixed dose of Hydroxyurea over the last 3 months. Patients were divided into two groups: a group that received Metformin for 6 months (Metformin group) and a control group. Complete blood picture, reticulocytic count, hemoglobin electrophoresis, liver enzymes, bilirubin, kidney functions, LDH and random blood sugar were performed at onset, 3 and 6 months of the study. All adverse events were recorded.

resultsForty two patients aged 12-23 years were enrolled. Metformin intake over 6 months did not show any statistically significant difference in clinical or the laboratory variables of efficacy when compared to the control group apart from reticulocytic count which was higher in Metformin group throughout the study.

conclusionMetformin intake, in addition to hydroxyurea, did not yield any extra benefit among patients with NTDT.

Indexed as

HbFHydroxyureaMetforminNon transfusion dependent thalassemia

Identifiers

PMID38312174
PMCPMC10831011
OpenAlexW4382766103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.